Trial · NCT06799650
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
NCT06799650, Phase 2, Active not recruiting, Federal University of São Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV. Trials, record NCT06799650. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06799650
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
- NCT number
- NCT06799650
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Federal University of São Paulo
- Conditions
- HIV Seropositivity
- Interventions
- Gammora®
- First posted
- 2025-01-29
- Last updated
- 2026-06-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Proviral HIV DNA quantitation | Weekly from time of randomization for 27 consecutive weeks | Total HIV DNA measured by qPCR |
| Primary | Episomal Proviral HIV DNA quantitation | Weekly from time of randomization for 27 consecutive weeks | Episomal HIV DNA measured by qPCR |
| Primary | Apoptosis markers | Three times per week during from randomization to week 3 and weekly from that point through week 27 | Evaluated by flow cytometry exclusively in the CD4+ T cell gates, using the PE Annexin V Apoptosis Detection kit (BD Biosciences) |
| Secondary | HIV Viral load | Weekly from time of randomization for 27 consecutive weeks | Viral RNA in copies per mL of plasma |
| Secondary | CD4 T cell counts | Weekly from time of randomization for 27 consecutive weeks | CD4+ T cell count per mL |
| Secondary | CD8 T cell counts | Weekly from time of randomization for 27 consecutive weeks | CD8+ T cell count per mL |
| Secondary | Levels of Lymphocyte T Cell activation markers (CD38 and HLA-DR in CD4 and CD8+ T cells) for each participant | Weekly for 12 weeks and every 4 weeks after that | CD38 and HLA-DR in CD4 and CD8+ T cell lymphocytes by flow cytometry |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Weekly for 12 weeks and every 4 weeks after that | A list of adverse events, separated by treatment-related or not treatment-related as assessed by CTCAE v4.0 per participant. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06799650
GET https://conductscience.org/api/trials/v1/NCT06799650/registered